PIM2 and acute lymphoblastic leukemia: This elevated expression of PIM2 is associated with poor prognoses in ALL patients, resulting from an increased resistance in leukemic cells to apoptosis, and its clinical significance is associated with low complete-remission rates, shorter leukemia-free survival times, higher-risk cytogenetics, and shorter event-free survival times 34.